β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Overview

Journal Pathogens

Date 2025 Feb 26

PMID 40005543

Authors

Angeliki Katsarou

Panagiotis Stathopoulos

Iva D Tzvetanova

Christina-Maria Asimotou

Matthew E Falagas

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of β-lactams/β-lactamase inhibitors against multidrug-resistant (MDR) Gram-negative pathogens, which remain the major concern in clinical practice. The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria. Currently, many combinations are being studied for their in vitro activity against both serine- and metallo-β-lactamases. However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials.

References

Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore D . Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2018; 74(4):953-960. DOI: 10.1093/jac/dky522. View

Dubey D, Roy M, Shah T, Bano N, Kulshrestha V, Mitra S . Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced.... Ann Clin Microbiol Antimicrob. 2023; 22(1):55. PMC: 10324185. DOI: 10.1186/s12941-023-00606-x. View

Keam S . Cefepime/Enmetazobactam: First Approval. Drugs. 2024; 84(6):737-744. DOI: 10.1007/s40265-024-02035-2. View

Beninger P . Ceftobiprole Medocaril Sodium. Clin Ther. 2024; 46(8):659-660. DOI: 10.1016/j.clinthera.2024.06.007. View

Bhagwat S, Periasamy H, Takalkar S, Palwe S, Khande H, Patel M . The Novel β-Lactam Enhancer Zidebactam Augments the Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Infection Model. Antimicrob Agents Chemother. 2019; 63(4). PMC: 6437547. DOI: 10.1128/AAC.02146-18. View

Moya B, Bhagwat S, Cabot G, Bou G, Patel M, Oliver A . Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. J Antimicrob Chemother. 2020; 75(6):1474-1478. DOI: 10.1093/jac/dkaa036. View

Huang Z, Yang X, Jin Y, Yu J, Cao G, Wang J . First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects. Antimicrob Agents Chemother. 2023; 68(1):e0133023. PMC: 10777830. DOI: 10.1128/aac.01330-23. View

Lomovskaya O, Tsivkovski R, Totrov M, Dressel D, Castanheira M, Dudley M . New boronate drugs and evolving NDM-mediated beta-lactam resistance. Antimicrob Agents Chemother. 2023; 67(9):e0057923. PMC: 10508144. DOI: 10.1128/aac.00579-23. View

Rodvold K, Gotfried M, Chugh R, Gupta M, Patel A, Chavan R . Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105785. DOI: 10.1128/AAC.00682-18. View

10.

Tamma P, Heil E, Justo J, Mathers A, Satlin M, Bonomo R . Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024; . DOI: 10.1093/cid/ciae403. View

11.

cerniauskiene K, Dambrauskiene A, Vitkauskiene A . Associations between -Lactamase Types of and Antimicrobial Resistance. Medicina (Kaunas). 2023; 59(8). PMC: 10456718. DOI: 10.3390/medicina59081386. View

12.

Pais G, Chang J, Barreto E, Stitt G, Downes K, Alshaer M . Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022; 61(7):929-953. PMC: 9345683. DOI: 10.1007/s40262-022-01137-y. View

13.

Tirlangi P, Wanve B, Dubbudu R, Yadav B, Kumar L, Gupta A . Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell.... Antimicrob Agents Chemother. 2023; 67(8):e0050023. PMC: 10433839. DOI: 10.1128/aac.00500-23. View

14.

Yahav D, Giske C, Gramatniece A, Abodakpi H, Tam V, Leibovici L . New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). PMC: 7667665. DOI: 10.1128/CMR.00115-20. View

15.

Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P . Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?. GMS Hyg Infect Control. 2017; 12:Doc05. PMC: 5388835. DOI: 10.3205/dgkh000290. View

16.

Moya B, Barcelo I, Bhagwat S, Patel M, Bou G, Papp-Wallace K . WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444176. DOI: 10.1128/AAC.02529-16. View

17.

Mojica M, Rossi M, Vila A, Bonomo R . The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2021; 22(1):e28-e34. PMC: 8266270. DOI: 10.1016/S1473-3099(20)30868-9. View

18.

Poudel A, Zhu S, Cooper N, Little P, Tarrant C, Hickman M . The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS One. 2023; 18(5):e0285170. PMC: 10166566. DOI: 10.1371/journal.pone.0285170. View

19.

Livermore D, Mushtaq S, Warner M, Vickers A, Woodford N . In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother. 2017; 72(5):1373-1385. DOI: 10.1093/jac/dkw593. View

20.

Almarzoky Abuhussain S, Avery L, Abdelraouf K, Nicolau D . Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model. Antimicrob Agents Chemother. 2018; 63(1). PMC: 6325183. DOI: 10.1128/AAC.01931-18. View